medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2022, Number 2

Next >>

Rev Cubana Hematol Inmunol Hemoter 2022; 38 (2)

Cytogenetic and molecular aspects in myelodysplastic syndromes

Lavaut SK, González GS

Language: Spanish
References: 44
Page: 1-15
PDF size: 301.54 Kb.


ABSTRACT

Introduction: Myelodysplastic syndromes constitute a heterogeneous group of alterations of the hematopoietic progenitor cell, characterized by hypercellular bone marrow, ineffective hematopoietic, dysplasia and peripheral cytopenia; and the possibility of progressing to acute myeloid leukemia.
Objective: To describe the most frequent cytogenetic and molecular alterations of myelodysplastic syndromes.
Methods: A review of the literature in English and in Spanish was carried out, in the PubMed website and using the search engine Google, for articles published in the last five years. We performed analysis and summary of the reviewed bibliography.
Analysis and synthesis of information: In myelodysplastic syndromes, frequent cytogenetic alterations are present such as deletion of chromosomes 5q, 7q and 20q, as well as the monosomy of chromosome 7, trisomy of chromosome 8 and the presence of complex karyotypes, which together with somatic mutations in different genes intervene in the pathogenesis of the disease and allow prognostic stratification of patients.
Conclusions: Diagnosis through conventional cytogenetic studies, fluorescence in situ hybridization and gene sequencing allow a better understanding of the biology of the disease, risk stratification and therapeutic decision making.


REFERENCES

  1. Fernández ND. Síndromes mielodisplásicos: una mirada al último Decenio. Rev Cubana Hematol, Inmunol y Hemoter. 2016 [acceso 21/06/2021];32(4): Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/4841.

  2. Hellström E, Tobiasson N, Greenberg P. Myelodysplastic syndromes: moving towards personalized management. Haematologica. 2020;105(7):1765-79. DOI: https://10.3324/haematol.2020.2489552.

  3. Bannon SA, DiNardo CD. Hereditary Predispositions to Myelodysplastic Syndrome. Int J Mol Sci. 2016;17(6):838. DOI: https://10.3390/ijms170608383.

  4. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le beau MM, et al. The updated Who classification of hematological malignancies. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405. DOI: https://10.1182/blood-2016-03-6435444.

  5. Awada H, Thapa B, Visconte V. The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications. Cells. 2020;9:2512. DOI: https://10.3390/cells91125125.

  6. Andreevna Y, Evgenievich S, Borisovich I, Ivanovna T, Fyodorovich I. Prognostic Markers of Myelodysplastic Syndromes. Medicina. 2020;56:376. DOI: https://10.3390/medicina560803766.

  7. Hasserjian RP. Myelodysplastic Syndrome Updated. Pathobiol. 2019;86:7-13. DOI: https://10.1159/0004897027.

  8. Song Q, Peng M, Chu Y, Huang S. Techniques for detecting chromosomal aberrations in myelodysplastic syndromes. Oncotarget. 2017;8(37):62716-29. DOI: https://10.18632/oncotarget.176988.

  9. Arias-Mira DE. Síndrome de deleción del 5q. Rev Hematol Mex. 2020;21(1):56-60. DOI: https://doi.org/10.24245/rev_hematol.v21i1.35549.

  10. Mortensen TB, Frederiksen H, Marcher CW, Preiss B. Refractory primary immune thrombocytopenia with subsequent del(5q) MDS: complete remission of both after lenalidomide. BMJ Case Rep. 2017;4:2017. DOI: https://10.1136/bcr-2016-21588810.

  11. Jädersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Göhring G, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011; 29(15):1971_9. DOI: https://10.1200/JCO.2010.31.857611.

  12. Zemanova Z, Michalova K, Buryova H, Brezinova J, Kostylkova K, Bystricka D, et al. Involvement of deleted chromosome 5 in complex chromosomal aberrations in newly diagnosed myelodysplastic syndromes (MDS) is correlated with extremely adverse prognosis. Leuk Res. 2014;38(5):537_44. Disponible en: https://doi.org/10.1016/j.leukres.2014.01.01212.

  13. Schneider RK, Schenone M, Ferreira MV, Kramann R, Joyce CE, Hartigan C, et al. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat Med. 2016;22(3):288_97. DOI: https://10.1038/nm.404713.

  14. Kuzmanovic T, Patel BJ, Sanikommu SR, Nagata Y, Awada H, Kerr CM, et al. Genomics of therapy-related myeloid neoplasms. Hematological. 2020;105(3):e98_e101. DOI: https://10.3324/haematol.2019.21935214.

  15. Wong JC, Weinfurtner KM, Alzamora MP, Kogan SC, Burgess MR, Zhang Y, et al. Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis. Elife. 2015;4:e07839. DOI: https://10.7554/eLife.0783915.

  16. Hasegawa N, Oshima M, Sashida G, Matsui H, Koide S, Saraya A, et al. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome. Leukemia. 2017;31(4):861_71. DOI: https://10.1038/leu.2016.26816.

  17. Hasle H. Myelodysplastic and myeloproliferative disorders of childhood. Hematology Am Soc Hematol Educ Program. 2016;2016(1):598_604. DOI: https://10.1182/asheducation-2016.1.59817.

  18. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia- Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454_65. DOI: https://10.1182/blood-2012-03-42048918.

  19. Cumbo C, Tota G, Anelli L, Zagaria A, Specchia G, Albano F. TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings. Int J Mol Sci. 2020;21:3432. DOI: https://10.3390/ijms2110343219.

  20. Abáigar M, Robledo C, Benito R, Ramos F, Díez-Campelo M, Hermosín L, et al. Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes. PLoS One. 2016;11(10):e0164370. DOI: https://10.1371/journal.pone.016437020.

  21. Yan X, Wang L, Jiang L, Luo Y, Lin P, Yang W, et al. Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes. Cancer Med.2021;10(5):1759_71. DOI: https://10.1002/cam4.378621.

  22. Jiang L, Wang L, Shen C, Zhu S, Lang W, Luo Y, et al. Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes. Am J Cancer Res. 2020;10(12):4476-87.

  23. Haferlach T. The Molecular Pathology of Myelodysplastic Syndrome. Pathobiol. 2019;86(1):24_9. DOI: https://10.1159/00048871223.

  24. Gill H, Leung A, Kwong YL. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy. Int J Mol Sci. 2016;17(4):440. DOI: https://10.3390/ijms1704044024.

  25. Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, et al. SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - a proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). Blood. 2020;136(2):157-70. DOI: https://10.1182/blood.202000485025.

  26. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012;119(2):569_72. DOI: https://10.1182/blood-2011-09-37799426.

  27. Visconte V, Tiu RV, Rogers HJ. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. Blood Res. 2014;49(4):216-27. DOI: https://10.5045/br.2014.49.4.21627.

  28. Liang Y, Tebaldi T, Rejeski K, Joshi P, Stefani G, Taylor A, et al. SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells. Leukemia. 2018;32(12):2659_71. DOI: https://10.1038/s41375-018-0152-728.

  29. Traina F, Visconte V, Elson P, Tabarroki A, Jankowska AM, Hasrouni E, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014;28(1):78_87. DOI: https://10.1038/leu.2013.26929.

  30. Bejar R, Lord A, Stevenson K, Bar-Natan M, Perez-Ladaga A, Zaneveld J, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705-12. DOI: https://10.1182/blood-2014-06-58280930.

  31. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012;30(27):3376-82. DOI: https://10.1200/JCO.2011.40.737931.

  32. Bejar R. Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica. 2014;99(6):956-64. DOI: https://10.3324/haematol.2013.08521732.

  33. Xu F, Liu L, Chang CK, He Q, Wu LY, Zhang Z, et al. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome. Oncotarget. 2016;7(7):8119_30. DOI: https://10.18632/oncotarget.699233.

  34. Hasegawa N, Oshima M, Sashida G, H Matsuai, S Koide, A Saraya, et al. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome. Leukemia. 2017;31:861_71. DOI: https://doi.org/10.1038/leu.2016.26834.

  35. Harada Y, Inoue D, Ding Y, Imagawa J, Doki N, Matsui H, et al. RUNX1/AML1 mutant collaborates with BMI1 overexpression in the development of human and murine myelodysplastic syndromes. Blood. 2013;121(17):3434_46. DOI: https://10.1182/blood-2012-06-43442335.

  36. Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, et al. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019;33(7):1747_58. DOI: https://10.1038/s41375-018-0351-236.

  37. Ren T, Wang J, Zhang H, Mei Ch, Ye L, Luo Y, et al. TP53 mutations are associated with very complex karyotype and suggest poor prognosis in newly diagnosed myelodysplastic syndrome patients with monosomal karyotype. Asia-Pacific J of Clin Oncol. 2020;16(3):172-9. DOI: https://doi.org/10.1111/ajco.1331637.

  38. Zeinali T, Mansoori B, Mohammadi A. Regulatory mechanisms of miR-145 expression and the importance of its function in cancer metastasis. Biomed Pharmacother. 2019;109:195-207. DOI: https://doi.org/10.1016/j.biopha.2018.10.03738.

  39. Caponetti GC, Bagg A. Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges. Int J Lab Hematol. 2020;42(6):67184. DOI: https://doi.org/10.1111/ijlh.1328439.

  40. Swoboda DV, Ali NA, Chan O, Padron E, Kuykendall AT, Song J, et al. PTPN11 mutations are associated with poor outcomes across myeloid malignancies. Leukemia. 2021;35:286_8. DOI: https://doi.org/10.1038/s41375-020-01083-340.

  41. Viny AD, Levine RL. Cohesin mutations in myeloid malignancies made simple. Curr Opin Hematol. 2018;25(2):61_6. DOI: https://10.1097/MOH.000000000000040541.

  42. Churpek JE. Familial myelodysplastic syndrome/acute myeloid leukemia. Best Pract Res Clin Haematol. 2017;30(4):287-9. DOI: https://10.1016/j.beha.2017.10.00242.

  43. Godley LA, Shimamura A. Genetic predisposition to hematologic malignancies: management and surveillance. Blood. 2017;130(4):424-32. DOI: https://10.1182/blood-2017-02-73529043.

  44. Godley Lucy A. Germline mutations in MDS/AML predisposition disorders. Curr Opinion Hematol. 2021;28(2):86-93. DOI: https://10.1097/MOH.000000000000063344.




2020     |     www.medigraphic.com